Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Compass Pathways

Psychedelic Stock Gainers And Losers From June 14, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 9.90% at $9.44

Benzinga

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS:

Benzinga

Psychedelic Stock Gainers And Losers From May 12, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.44% at $7.06

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Compass Pathways Reports Q1 Financial Results, With Increased R&D Expenses Compared To 2021

Compass Pathways (NASDAQ: CMPS) announced its financial results for the first quarter of 2022, which ended March 31. Q1 Results For the first three months of the year, net loss was $21.2 million, or $0.50 loss per share. For comparison, net loss in the same period of 2021 was $12.7 million…

Benzinga

Intelgenx Technologies, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 16.68% at $0.26

Benzinga

Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs

Psychedelics policy action took center stage this week.

Benzinga

Compass Pathways: Q1 Earnings Insights

Compass Pathways (NASDAQ:CMPS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

A Preview Of Compass Pathways's Earnings

Compass Pathways (NASDAQ:CMPS) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Compass Pathways will report an earnings per share (EPS) of $-0.67.

Benzinga

New Study To Evaluate Magic Mushroom's Therapeutic Potential On Autistic Adults

Psychedelics continue to garner attention as possible treatments for diverse mental health conditions. Now, Compass Pathways (NASDAQ: CMPS) will undertake a study to evaluate psilocybin’s effects on autistic adults.

Benzinga

2 New Studies Look At Compass Pathways' Psilocybin Drug For Anorexia And Depression

Compass Pathways (Nasdaq: CMPS), a company developing psychedelic pharmaceutical drugs for the mental health space, announced the publication of two new investigator-initiated studies using its flagship compound, COMP360.

Benzinga

Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 8.17% at $9.80

Benzinga

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.97% at $4.97

Benzinga

Christian Angermayer Buys 1 Million Shares Of Atai Life, His Own Company

Christian Angermayer, founder and chairman of Atai Life Sciences (NASDAQ:ATAI), told Twitter that he bought 1 million shares of his company. “Many #biotech stocks are cheap at the moment. In my opinion, Atai Life Sciences AG stands out though for two reasons: the size of the market (unfortunately) the fact…

Benzinga

Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.06% at $14.18

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results

atai Life Sciences N.V. (NASDAQ:ATAI) has announced its financial results for the fourth quarter and full year ended December 31, 2021. 2021 Financial Results Highlights included: Positive Phase 2b data with COMP360 from a ground-breaking treatment-resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment…

Benzinga

Top 5 Most Influential Psychedelic Studies

This article was originally published on Psychedelic Spotlight and appears here with permission. While psychedelic studies now number in the thousands since Western research began in the 1950s, we unpack five of the most important in recent years as psychedelics are on the cusp of becoming mainstream medicines. When it…

Benzinga

Psyched: Third Michigan City Decriminalizes Psychedelics, MindMed Reports $133M Cash Position, Real Brands To Enter The Space

The psychedelics legislative landscape continues to move forward with Hazel Park, Michigan enacting decriminalization measures for naturally-produced psychedelic molecules, becoming the third city in the state to do so after Ann Arbor and Detroit. In Utah, Governor Cox signed a psychedelics research bill into law and positive legislation around psilocybin is continuing…

Benzinga

Can Psychedelics Like MDMA Cure Eating Disorders?

This article was originally published on Psychedelic Spotlight and appears here with permission. Multidisciplinary Association for Psychedelic Studies (MAPS) published a study which found that MDMA-assisted therapy significantly reduced symptoms of eating disorders. Anyone who has ever suffered from an eating disorder, such as anorexia or bulimia, knows that beating…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

UK: COMPASS Pathways Forms Partnership To Launch Centre For Mental Health Research And Innovation

COMPASS Pathways plc (NASDAQ:CMPS) has announced the formation of a long-term partnership with the South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry, Psychology Neuroscience at King’s College London. The aim of this collaboration is to launch The Centre for Mental Health Research and Innovation, whose…

Benzinga

Psychedelic Stock Gainers And Losers From March 23, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 5.32% at $13.45 LOSERS:

Benzinga

Mindset Pharma, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 6.03% at $1.23

Benzinga

These Private Psychedelics Companies Have Raised Impressive Amounts Of Money

Throughout the last decade, more and more companies have popped up that are focused on discovering and developing psychedelic compounds to revolutionize the treatment of mental illness. A number of these companies, including Atai Life Sciences (NASDAQ:ATAI) and Compass Pathways (NASDAQ:CMPS) are already publicly traded. But today we will take a…

Benzinga

Compass Pathways Earnings Preview

Compass Pathways (NASDAQ:CMPS) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts estimate that Compass Pathways will report an earnings per share (EPS) of $-0.50.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Psychedelic Spotlight

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.